Pfizer raised the midpoint of its 2026 revenue guidance by USD 500 million to USD 60.5 billion-USD 62.5 billion.
Updated outlook reflects stronger non-COVID performance, offset by lower COVID-19 revenue expectations of about USD 4 billion versus about USD 5 billion.
Adjusted diluted EPS guidance reaffirmed at USD 2.8-USD 3 despite an expected USD 0.1 hit from a USD 650 million acquired IPR&D charge.
Second-quarter revenue was USD 15 billion, up 1% operationally; adjusted diluted EPS was USD 0.77.
Plan assumes most Comirnaty sales land late in the year; low COVID-19 incidence seen limiting Paxlovid utilization.
PFE•
